Clapton Dias

1.8k total citations · 1 hit paper
20 papers, 1.4k citations indexed

About

Clapton Dias is a scholar working on Surgery, Pharmacology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Clapton Dias has authored 20 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Surgery, 5 papers in Pharmacology and 4 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Clapton Dias's work include Lipoproteins and Cardiovascular Health (5 papers), Herpesvirus Infections and Treatments (4 papers) and Biosimilars and Bioanalytical Methods (3 papers). Clapton Dias is often cited by papers focused on Lipoproteins and Cardiovascular Health (5 papers), Herpesvirus Infections and Treatments (4 papers) and Biosimilars and Bioanalytical Methods (3 papers). Clapton Dias collaborates with scholars based in United States, Australia and Germany. Clapton Dias's co-authors include Ashim K. Mitra, Jane R. Parnes, Gail M. Gauvreau, Beth E. Davis, Michael Boedigheimer, Michael R. Comeau, Ying Wang, Donald W. Cockcroft, Paul M. O’Byrne and Richard Leigh and has published in prestigious journals such as New England Journal of Medicine, Circulation and Journal of the American College of Cardiology.

In The Last Decade

Clapton Dias

20 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effects of an Anti-TSLP Antibody on Allergen-Induced Asthmatic Responses

2014 587 citations Gail M. Gauvreau, Paul M. O’Byrne et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Clapton Dias United States	14	506	392	340	253	251	20	1.4k
André B. Mulder Netherlands	24	106 0.2×	260 0.7×	293 0.9×	236 0.9×	48 0.2×	70	1.9k
Scott Baumgartner United States	20	180 0.4×	684 1.7×	769 2.3×	24 0.1×	18 0.1×	52	2.0k
F. Bruni Italy	19	35 0.1×	390 1.0×	168 0.5×	330 1.3×	30 0.1×	53	843
Xiaohui Zeng China	21	76 0.2×	247 0.6×	79 0.2×	39 0.2×	69 0.3×	83	1.4k
David Rubin United States	22	516 1.0×	175 0.4×	142 0.4×	113 0.4×	58 0.2×	56	1.7k
Roland Klingenberg Switzerland	27	86 0.2×	918 2.3×	730 2.1×	712 2.8×	76 0.3×	86	2.3k
Max‐Paul Winter Austria	23	84 0.2×	379 1.0×	446 1.3×	798 3.2×	46 0.2×	72	1.7k
Barbara Hunt United States	27	86 0.2×	1.6k 4.0×	247 0.7×	85 0.3×	52 0.2×	68	3.0k
A. van den Ende Netherlands	16	93 0.2×	290 0.7×	186 0.5×	153 0.6×	8 0.0×	42	1.4k
Lucia Novelli Italy	19	226 0.4×	84 0.2×	333 1.0×	52 0.2×	36 0.1×	49	1.4k

Countries citing papers authored by Clapton Dias

Since Specialization

Citations

This map shows the geographic impact of Clapton Dias's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Clapton Dias with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Clapton Dias more than expected).

Fields of papers citing papers by Clapton Dias

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Clapton Dias. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Clapton Dias. The network helps show where Clapton Dias may publish in the future.

Co-authorship network of co-authors of Clapton Dias

This figure shows the co-authorship network connecting the top 25 collaborators of Clapton Dias. A scholar is included among the top collaborators of Clapton Dias based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Clapton Dias. Clapton Dias is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lü, Hong, Wei‐Li Chen, Hongrong Xu, et al.. (2019). <p>A Phase 1, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Safety, Tolerability, And Pharmacokinetic/Pharmacodynamic Study Of Evolocumab In Healthy Chinese Subjects</p>. Clinical Pharmacology Advances and Applications. Volume 11. 145–153. 2 indexed citations

Parnes, Jane R., John T. Sullivan, Li Chen, & Clapton Dias. (2019). Pharmacokinetics, Safety, and Tolerability of Tezepelumab (AMG 157) in Healthy and Atopic Dermatitis Adult Subjects. Clinical Pharmacology & Therapeutics. 106(2). 441–449. 37 indexed citations

Vakkalagadda, Blisse, Charles Frost, Wonkyung Byon, et al.. (2016). Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa. American Journal of Cardiovascular Drugs. 16(2). 119–127. 82 indexed citations

Dias, Clapton, Kenneth Todd Moore, Joe Murphy, et al.. (2016). Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Rivaroxaban in Chronic Hemodialysis. American Journal of Nephrology. 43(4). 229–236. 93 indexed citations

Gibbs, John P., J. Greg Slatter, Ogo Egbuna, et al.. (2016). Evaluation of Evolocumab (AMG 145), a Fully Human Anti‐PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment. The Journal of Clinical Pharmacology. 57(4). 513–523. 19 indexed citations

Dias, Clapton, et al.. (2015). Tolerability of High-Volume Subcutaneous Injections of a Viscous Placebo Buffer: A Randomized, Crossover Study in Healthy Subjects. AAPS PharmSciTech. 16(5). 1101–1107. 47 indexed citations

Xu, Ren, Clapton Dias, Bing Gao, et al.. (2014). EFFECTS OF EVOLOCUMAB ON LIPOPROTEIN PARTICLES AND SUBCLASSES IN HYPERCHOLESTEROLEMIC AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA SUBJECTS ON STATIN THERAPY. Journal of the American College of Cardiology. 63(12). A1378–A1378. 2 indexed citations

Gauvreau, Gail M., Paul M. O’Byrne, Louis‐Philippe Boulet, et al.. (2014). Effects of an Anti-TSLP Antibody on Allergen-Induced Asthmatic Responses. New England Journal of Medicine. 370(22). 2102–2110. 587 indexed citations breakdown →

Frost, Charles, Wonkyung Byon, Yan Song, et al.. (2014). Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factorXa inhibitor. British Journal of Clinical Pharmacology. 79(5). 838–846. 128 indexed citations

10.

Wasserman, Scott M., et al.. (2013). AMG-145. Drugs of the Future. 38(7). 451–451. 14 indexed citations

11.

Dias, Clapton, Adam J. Shaywitz, Scott M. Wasserman, et al.. (2012). Effects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels. Journal of the American College of Cardiology. 60(19). 1888–1898. 202 indexed citations

12.

Dias, Clapton, Adam J. Shaywitz, Blaire Cooke, et al.. (2012). EFFECTS OF AMG 145, A FULLY HUMAN MONOCLONAL ANTIBODY AGAINST PCSK9, ON LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN SUBJECTS TAKING STATINS: A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ASCENDING MULTIPLE-DOSE STUDY. Journal of the American College of Cardiology. 59(13). E1379–E1379. 18 indexed citations

13.

Shaywitz, Adam J., Clapton Dias, Brian P. Smith, et al.. (2012). AMG 145, a Fully Human Monoclonal Antibody Against PCSK9, Reduces LDL-C in Healthy Volunteers and Patients on Stable Doses of Statins†. Journal of clinical lipidology. 6(3). 286–287. 3 indexed citations

14.

Dias, Clapton, Adam J. Shaywitz, Brian D. Smith, et al.. (2011). Abstract 10701: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability and Pharmacodynamics of AMG145. Circulation. 124. 8 indexed citations

15.

Ganju, Jitendra & Clapton Dias. (2010). Rationale for Sponsor-unblinded Phase 1 Trials: Challenging the Double-blind Paradigm. Drug Information Journal. 44(1). 21–27. 2 indexed citations

16.

Dias, Clapton & Ashim K. Mitra. (2003). Posterior Segment Ocular Pharmacokinetics Using Microdialysis in a Conscious Rabbit Model. Investigative Ophthalmology & Visual Science. 44(1). 300–300. 10 indexed citations

17.

Tirucherai, Giridhar, Clapton Dias, & Ashim K. Mitra. (2002). Corneal Permeation of Ganciclovir: Mechanism of Ganciclovir Permeation Enhancement by Acyl Ester Prodrug Design. Journal of Ocular Pharmacology and Therapeutics. 18(6). 535–548. 37 indexed citations

18.

Dias, Clapton, et al.. (2002). Ocular penetration of acyclovir and its peptide prodrugs valacyclovir and val-valacyclovir following systemic administration in rabbits: An evaluation using ocular microdialysis and LC-MS. Current Eye Research. 25(4). 243–252. 37 indexed citations

19.

Dias, Clapton, Banmeet S. Anand, & Ashim K. Mitra. (2002). Effect of Mono‐ and Di‐acylation on the Ocular Disposition of Ganciclovir: Physicochemical Properties, Ocular Bioreversion, and Antiviral Activity of Short Chain Ester Prodrugs. Journal of Pharmaceutical Sciences. 91(3). 660–668. 44 indexed citations

20.

Dias, Clapton & Ashim K. Mitra. (2000). Vitreal Elimination Kinetics of Large Molecular Weight FITC‐Labeled Dextrans in Albino Rabbits Using a Novel Microsampling Technique. Journal of Pharmaceutical Sciences. 89(5). 572–578. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact